Morin inhibits fructose bisphosphate aldolase activity and resists Cryptosporidium parvum infection Authors: Mengge Chen, Hongyan Kang, Yanhui Yu, Xuancheng Zhang, Xu Zhang, Xiaocen Wang, Zhenzhen Liu, Yuan Zheng, Pengtao Gong, Nan Zhang, Xin Li, Jianhua Li Published: 2026 ABSTRACT AbstractCryptosporidium parvum is a zoonotic intestinal protozoan that causes severe diarrhea in children and immunocompromised individuals. The lack of effective therapies underscores the urgent need for novel drug targets. As C. parvum primarily relies on glycolysis for energy, fructose-1,6-bisphosphate aldolase (FBA) represents a promising target. Here, we characterized CpFBA and evaluated its potential as a therapeutic target. Sequence analysis revealed that CpFBA contains a signature domain associated with the type I fructose-bisphosphate aldolase superfamily and adopts a tetrameric structure. CpFBA protein localizes to both the cytoplasm and membrane of C. parvum sporozoites and presents in C. parvum excretory-secretory products (ESPs). Recombinant CpFBA protein (rCpFBA) exhibits typical aldolase activity, with a higher affinity for fructose-1,6-bisphosphate (FBP) (Km = 81.23 μM). Subsequently, molecular docking computationally predicted that morin may potentially bind to CpFBA. Anti-CpFBA serum or morin treatment significantly reduces glucose uptake and ATP levels of C. parvum sporozoites, and decreases parasite number in vitro. In C. parvum-infected suckling mice, morin treatment (60 mg/kg/day) significantly reduces oocyst shedding by 61.8%, alleviates C. parvum-induced weight loss and intestinal damage, preserves the expression of tight junction proteins (ZO-1, occludin), and suppresses the production of pro-inflammatory cytokines. These findings suggest that CpFBA is a promising drug target against C. parvum, and the natural compound morin resists C. parvum infection.Keywords: Cryptosporidium parvum; Fructose-1,6-bisphosphate aldolase; Morin; Drug target Introduction Cryptosporidium parvum is a globally distributed protozoan capable of infecting humans and a broad spectrum of animals, leading to cryptosporidiosis, which is commonly associated with cattle, particularly calves. The parasite primarily colonizes the small intestine and provokes a self-limiting diarrheal disease in immunocompetent patients. However, immunocompromised patients infected with C. parvum may develop severe and life-threatening complications characterized by profound malabsorption and wasting syndrome (Gomez-Puerta et al., 2020; Current and Garcia, 1991). Numerous outbreaks of cryptosporidiosis worldwide have been linked to recreational water venues, including swimming pools and water playgrounds. Although cryptosporidiosis causes significant economic losses and global public health, nitazoxanide remains the only therapeutic drug approved by the U.S. Food and Drug Administration (FDA), and its efficacy is markedly limited in immunocompromised patients (Capparelli and Syed, 2008). Furthermore, no safe and effective alternative drugs or vaccines against C. parvum have been developed (Pirovich et al., 2021). Therefore, identifying novel drug targets is essential for advancing the development of effective therapeutic interventions against cryptosporidiosis. Cryptosporidium enzymes and factors involved in core metabolic pathways, such as energy metabolism, fatty-acid activation and elongation, nucleotide and protein synthesis, and post-translational modifications, have served as drug targets against cryptosporidiosis (Zhang et al., 2015; Zhu, 2004; Pawlowic et al., 2019; Vinayak et al., 2020; Manjunatha et al., 2017). A range of anti-cryptosporidial hits and lead compounds have been generated by inhibiting the key enzymes of C. parvum, including vorinostat targeting histone deacetylase (Guo et al., 2018), KDU731 targeting phosphatidylinositol-4-kinase (Manjunatha et al., 2017), triacsin C targeting fatty-acyl-CoA synthetase (Guo et al., 2014), BKI-1708 and BKI-1553 targeting calcium-dependent protein kinase 1 (Huang et al., 2019a). Many compounds have exhibited well-defined inhibitory kinetics, nanomolar potency in vitro, high selectivity indices, and promised efficacy in vivo (Khan and Witola, 2023; Lenière et al., 2024). Furthermore, given the absence of functional mitochondria capable of performing the Krebs cycle and cytochrome-based electron transport, C. parvum appears to depend primarily on glycolysis for its metabolic energy production (Xu et al., 2024). Key glycolytic enzymes such as C. parvum pyruvate kinase and lactate dehydrogenase represent viable therapeutic targets for combating this parasite (Li et al., 2019a; Khan et al., 2022). Therefore, targeting the enzymes involved in glycolysis to screen for drugs against cryptosporidiosis may be more meaningful. Fructose-1,6-bisphosphate aldolase (FBA) is a crucial enzyme in the glycolytic pathway, catalyzing the reversible cleavage of FBP into dihydroxyacetone phosphate (DHAP) and glyceraldehyde-3-phosphate (GAP). FBA has been found in several pathogenic bacteria and fungi as both a drug target and a vaccine candidate, including Neisseria meningitidis, Staphylococcus aureus, and Candida albicans (Tunio et al., 2010; Yadav et al., 2013; Han et al., 2017). This enzyme also plays a significant role in the energy metabolism of protozoan parasites and has been identified as a potential target against Plasmodium and Leishmania donovani (Pirovich et al., 2021; Starnes et al., 2009). However, CpFBA has yet to be characterized. Further investigation into the molecular and biochemical properties of CpFBA, along with its potential as a druggable target, is of paramount importance. In this study, we analyzed the structural features of CpFBA through computational modeling and characterized its enzymatic properties through biochemical analyses. Additionally, the function of CpFBA was evaluated by antibody inhibition assays. Computational molecular docking revealed morin may bind to CpFBA, we further investigated the inhibitory effect of morin on CpFBA enzyme activity, as well as its efficacy against C. parvum in cellular and suckling mouse models. Materials and methods Animals, parasites, and cells Specific pathogen-free C57BL/6 mice and rabbits were obtained from Liaoning Changsheng Biological Company (Benxi, China). Animals were housed under controlled conditions (22 ± 2°C, 50–60% humidity, 12 h light/dark cycle) with free access to sterilized food and water. Seven-day-old suckling mice were used for infection experiments. HCT-8 cells were maintained in our laboratory. C. parvum (IOWA-II isolate) propagated in calves was used throughout this study, with oocysts purified via sucrose gradient centrifugation and stored at 4°C in PBS containing 200 U/mL penicillin and 0.2 mg/mL streptomycin (Beyotime, Shanghai, China). Bioinformatic analyses of CpFBA The C. parvum FBA gene (cgd1_3020) was retrieved from CryptoDB (https://cryptodb.org/cryptodb/app). Functional domains were predicted using InterProScan, and the domain architecture was visualized with IBS 2.0. The amino acid sequence of CpFBA (Q5CSE9) was obtained from the UniProtKB (https://www.uniprot.org/). Since no experimental structure of CpFBA is available, a homology model was generated using SWISS-MODEL (https://swissmodel.expasy.org/) with the Toxoplasma gondii FBA structure (PDB: 5TJS) as the template. Multiple sequence alignment and phylogenetic tree construction were performed using DNAMAN and MEGA12 (Neighbor-Joining, 1000 bootstrap replicates). Recombinant CpFBA expression and antibody preparation The CpFBA ORF was amplified from C. parvum genomic DNA and cloned into pGEX-4T-1 vector. Primers are listed in Supplementary Table 1 rCpFBA was expressed in Escherichia coli BL21 (DE3) with 0.1 mM IPTG at 37°C for 6 h and purified by glutathione-affinity chromatography (Solarbio, Beijing, China). Purified rCpFBA was verified by SDS-PAGE and Western blot using rabbit anti-GST antibody (1:5000 dilution; TransGen, Beijing, China). Anti-CpFBA polyclonal serum was generated by immunizing rabbits with purified rCpFBA emulsified in Freund's adjuvant (Sigma, MO, USA). Antibody specificity was verified by Western blot. Enzyme kinetics assay CpFBA activity was measured using an NADH-coupled assay. Reactions contained 200 ng rCpFBA, 50 mM Tris-HCl (pH 7.5), 0.3 mM NADH, 0.2 mg/mL BSA, 1 U/mL triosephosphate isomerase, 1 U/mL α-glycerophosphate dehydrogenase, and 0.2 mM FBP. Absorbance at 340 nm was monitored (Gao et al., 2018). Optimal pH and temperature were determined across pH 5.5-9.0 and 10-75°C. For the enzyme kinetic analysis, the assay was performed in 50 mM Tris-HCl buffer (pH7.5) at 37°C, and absorbance values at 340 nm were recorded at 1-min intervals. Initial reaction rates were measured at varying concentrations of FBP (25, 50, 75, 100, 150, 200, 300 μM). The Michaelis constant (Km) and maximum reaction velocity (Vmax) were determined by fitting the data to the Michaelis-Menten equation using Lineweaver-Burk plots (Gao et al., 2018). Subcellular localization and secretory analysis of CpFBA For subcellular localization of CpFBA, C. parvum sporozoites were fixed, permeabilized, and incubated with anti-CpFBA serum (1:200) for 2 h at room temperature (RT), followed by incubation with CoraLite Plus 488-conjugated secondary antibody (1:200; Proteintech, Wuhan, China). After three washes with PBS, slides were sealed with Hoechst-containing anti-fluorescence quench agent (Beyotime, Shanghai, China). Images were captured using confocal microscopy (Olympus, Tokyo, Japan). For secretion analysis, sporozoites were incubated in RPMI 1640 at 37°C for 3 h, and excretory-secretory products (ESPs) were collected by centrifugation (12,000 g for 10 min at 4°C). CpFBA presence in ESPs was detected by Western blot using anti-CpFBA polyclonal serum. Quantitative real-time PCR (qPCR) To examine the transcriptional levels of CpFBA at different developmental stages of C. parvum, HCT-8 cells were infected with C. parvum and harvested at 0, 3, 8, 18, 24, and 48 h post-infection. Total RNA was extracted from the infected cells (containing a mixture of host and parasite RNA) using TRIzol reagent (Epizyme, Shanghai, China) and reverse-transcribed using the 5 × All-In-One RT Mastermix (Abm, CA, USA). qPCR was performed using SYBR Green qPCR Master Mix (Servicebio, Wuhan, China). CpFBA expression was normalized to C. parvum 18S rRNA, and fold changes were calculated using the 2−ΔΔCt method (Fei et al., 2018). CpFBA-2 and C. parvum 18S rRNA primers are listed in Supplementary Table 1. For parasite quantification in HCT-8 cells, the same procedure was the same as above. Total RNA (mixed host and parasite) was extracted, and the parasite load was determined by qPCR using primers specific for C. parvum 18S rRNA (Cp18S; see Supplementary Table 1). Host 18S rRNA (Hs18S) was used as an internal control to normalize the amount of total RNA when comparing different samples, as indicated in Supplementary Table 1. For oocyst quantification in feces, fecal genomic DNA was extracted from 2 mg fecal samples using a fecal DNA extraction kit (Tiangen, Beijing, China) according to the manufacturer's instructions. Each 20 μL qPCR reaction contained 200 ng of fecal DNA, 1 μL each of forward and reverse primers (10 μM) for C. parvum 18S rRNA, 10 μL of 2 × Universal SYBR Green qPCR Master Mix, and ddH2O to volume. Oocyst loads were quantified using a standard curve (107 to 100 oocysts) (Li et al., 2025). Anti-C. parvum effects test of anti-CpFBA serum in vitro Sporozoites were pre-incubated with anti-CpFBA serum (1:50, 1:100, 1:200) or pre-immune serum (1:50) for 1 h. Glucose uptake and ATP levels were measured using glucose levels using a glucose assay kit (Solarbio, Beijing, China) and ATP assay kit (Beyotime, Shanghai, China). Treated sporozoites were added to HCT-8 cells, parasite numbers were assessed by qPCR at 3 h and 44 h post-infection. Tight junction protein expression (ZO-1, Occludin) was analyzed by Western blot. Molecular docking The morin structure (CID: 5281670) was retrieved from PubChem (https://pubchem.ncbi.nlm.nih.gov), and the amino acid sequence of CpFBA (Q5CSE9) was obtained from the UniProtKB (https://www.uniprot.org/). A homology model of CpFBA was generated using SWISS-MODEL (https://swissmodel.expasy.org/) with the Toxoplasma gondii FBA structure (PDB: 5TJS) as the template. The resulting CpFBA model was used for subsequent docking analysis. AutoDock (version: 4.2.6, Scripps Research Institute, USA) was used to add all hydrogen atoms to the protein to be docked, calculated its charge number and determined the rigidity of the atom. A grid box (25 Å × 25 Å × 25 Å) was defined using the AutoGrid program, centered on the predicted active site of CpFBA based on alignment with the template. Molecular docking was performed using AutoDock with default parameters. From the docking results, the conformation with the lowest binding free energy was selected as the dominant binding pose. The final pose was visualized using PyMOL. Morin anti-C. parvum effects test Enzyme inhibition assays determined the IC50 of morin. The enzyme kinetics were assayed at various concentrations of morin (3.9, 7.8, 15.6, 31.2, 62.5, and 125 μM), and IC50 was calculated by nonlinear regression curve fitting. Sporozoites were pre-incubated with 12.5, 25, or 50 μM morin at 37°C for 1 h; Sporozoites pre-incubated with medium containing DMSO served as the control group (C.p), and similar assays were performed as described above (anti-CpFBA serum). Scanning Electron Microscopy (SEM) Sporozoites were incubated with 50 μM morin or DMSO in RPMI 1640 medium at 37°C for 1 h. After incubation, the sporozoites were fixed with electron microscopy fixative (Servicebio, Wuhan, China) overnight at 4°C. Subsequent processing was performed by Servicebio Company (Wuhan, China) following standard protocols. Samples were examined under a scanning electron microscope at 3 kV, and images were captured from at least five randomly selected fields per sample, the image acquisition and morphological assessment were performed by an investigator blinded to the treatment groups. Anti-C. parvum efficacy of morin in vivo Seven-day-old suckling mice were randomly divided into seven groups (n = 5): PBS control, C. parvum infection, infection + morin (20, 40, 60 mg/kg/day), solvent control (2% DMSO + 10% PEG 400 + 88% saline), and morin-only control (60 mg/kg/day). Mice were orally infected with 2 × 105 oocysts on day 1, followed by daily oral gavage of morin or vehicle from day 2 to day 6. On day 6. Feces were collected to detect the oocyst output; ileum tissues were collected, and proinflammatory cytokines were detected by qPCR, tissue damage was analyzed by hematoxylin and eosin (H&E) staining, Occludin and ZO-1 protein were detected using Western blot and immunofluorescence assay (IFA), and goblet cells were detected by Alcian blue-periodic acid-Schiff (AB-PAS) staining. Western blot analysis Protein lysates from sporozoites, HCT-8 cells, or ileum tissues, and equal amounts of protein were separated by SDS-PAGE and transferred to PVDF membranes (Millipore, Bedford, USA). Membranes were blocked with 5% skim milk in PBST at RT for 1 h and incubated overnight at 4°C with primary antibodies: anti-CpFBA serum (1:200), anti-occludin (1:1000; Diagbio, Hangzhou, China), anti-ZO-1 (1:1000; Immunoway, TX, USA), anti-GAPDH (1:5000; Proteintech, Wuhan, China). followed by HRP-conjugated secondary antibodies (1:5000; Proteintech, Wuhan, China) at RT for 1 h. After washing three times with PBST, the membrane was were visualized using chemiluminescence. Detecting inflammatory factors in the ileum of suckling mice by qPCR Total RNA from ileum tissues was extracted and reverse-transcribed as described above. qPCR was performed to measure IL-6, IL-12, and TNF-α mRNA levels, normalized to GAPDH. Primers are listed in Supplementary Table 1. Histopathological observation and AB-PAS staining Ileum tissues were fixed, paraffin-embedded, and sectioned. H&E staining was performed by Wuhan Servicebio Technology Company. For AB-PAS staining, ileum sections were dewaxed and hydrated, then stained using an AB-PAS staining kit (Servicebio, Wuhan, China) according to the manufacturer's protocol. Four non-overlapping images per sample were captured using an optical microscope. Immunofluorescence Assay (IFA) Paraffin sections were dewaxed, hydrated, and subjected to antigen retrieval in sodium citrate buffer. After blocking with 3% BSA, sections were incubated with anti-occludin (1:200), anti-ZO-1 (1:200), and anti-pan-Cryptosporidium antibody (Pan-Crypto) (1:200) overnight at 4°C. Following PBS washes, sections were incubated with Alexa Fluor 488-conjugated Affinipure Goat Anti-Rabbit IgG antibody and Alexa Fluor 594 goat anti-chicken IgY (H + L) (1:200; Proteintech, Wuhan, China) at RT for 1 h. Following PBS washes, sections were sealed with Hoechst-containing anti-fluorescence quenching agent (Beyotime, Shanghai, China). Images were captured using a confocal microscope, and fluorescence intensity was quantified using ImageJ. Statistical analysis All data are presented as mean ± SD from at least three independent experiments, and each experiment in vitro was performed with three biological replicates (n = 3), and in vivo experiments used five mice per group (n = 5). Statistical significance was evaluated using one- or two-way ANOVA or unpaired Student's t-test, analyses were performed using GraphPad Prism 9.5. Results CpFBA is a conserved tetrameric enzyme in apicomplexan protozoa To understand the structure and potential biological functions of CpFBA, bioinformatic analysis was performed. The results revealed that the CpFBA gene encoded a 1074 bp ORF. The InterPro Scan tool predicted that CpFBA contained a signature domain (residues 10-358) associated with the type I fructose-bisphosphate aldolase superfamily, which was involved in glycolysis and exhibited fructose-bisphosphate aldolase activity (Fig. 1A). Tertiary structure modeling was predicted using SWISS-MODEL with the Toxoplasma gondii FBA structure as the templatethat, found that CpFBA adopted a tetrameric quaternary structure (Fig. 1B). The phylogenetic tree showed significant interspecies conservation of FBA within Cryptosporidium spp., with CpFBA exhibiting the closest phylogenetic relationship to Cryptosporidium tyzzeri (99.16% similarity) and Cryptosporidium hominis (98.88% similarity) FBAs (Fig. 1C). Additionally, FBA was conserved among apicomplexan protozoa, clustering closely with FBAs from T. gondii, Plasmodium spp., Eimeria spp., and Babesia spp., sharing sequence identities ranging from 64.53% to 74.02% (Fig. 1C). These data reveal that CpFBA is a conserved tetrameric fructose-bisphosphate aldolase involved in glycolysis. Sequence characteristics of CpFBA. A. The functional domains of CpFBA were predicted using the InterPro Scan online tool, and domain diagram of CpFBA was drawn using IBS 2.0. B. The tertiary structure of CpFBA was determined using SWISS-MODEL. C. The phylogenetic tree analysis of multi-species FBA using MEGA 12. The tree was constructed by the Neighbo-Joining method with 1000 bootstrap replications. Recombinant CpFBA exhibits fructose-bisphosphate aldolase activity To validate the predicted function of CpFBA, rCpFBA was expressed and purified (Supplementary Fig. 1, Supplementary Fig. 2A–C), and its enzymatic properties were characterized by NADH-coupled enzyme assay. Comparison of CpFBA enzyme activity demonstrated that the optimal reaction temperature and pH values were 37°C and pH 7.5 respectively (Fig. 2A and B). rCpFBA completely converted the substrate within 10 min, whereas the GST-tag protein exhibited no catalytic activity (Fig. 2C). With FBP as the substrate, kinetic analysis revealed that rCpFBA displayed Michaelis-Menten kinetics, with a Km of 81.23 μM and a Vmax of 5.87 × 10−5 mol L−1·min−1 (Fig. 2D). Collectively, these data confirm that rCpFBA possesses robust FBA activity. Kinetic analysis of CpFBA. A, B. Analysis of the optimal temperature and pH for CpFBA by measuring the initial rate of the enzyme-catalyzed reaction. Michaelis-Menten curves were fitted to the data to determine kinetic parameters. C. CpFBA catalyzed the reaction of fructose-1,6-diphosphate, which was measured every 1 min and monitored continuously for 12 min. D. Variations in CpFBA activity at different FBP concentrations. All data are presented as mean ± SD of three independent experiments (n = 3). CpFBA localizes to the plasma membrane and cytoplasm of C. parvum and is highly expressed during early infection To gain insight into the potential roles of CpFBA, we investigated its subcellular localization and expression dynamics during the parasite development. Western blot analysis showed that anti-CpFBA serum recognized native CpFBA in C. parvum lysates, displaying specific band at approximately 38 kDa (Supplementary Fig. 2D). The purified rCpFBA was identified by anti-CpFBA serum at approximately 65.8 kDa (Supplementary Fig. 2E). IFA data revealed that CpFBA was localized both on the membrane and in the cytoplasm of C. parvum sporozoites (Fig. 3A). In addition, CpFBA was detected in CpESP by Western blot (Fig. 3B). To measure CpFBA expression levels at different developmental stages of C. parvum, mRNA levels were detected by qPCR. The results showed that CpFBA expression was peaked at 3 h post-infection, followed by a decline in subsequent developmental stages (Fig. 3C), suggesting that CpFBA is highly expressed during early infection. Analysis of subcellular localization, secretion characteristics, and the transcriptional patterns of CpFBA. A. The localization of CpFBA in sporozoites was detected using anti-CpFBA serum (green) by IFA. Hoechst (blue) denotes nuclei. Scale bars, 20 μm, and 5 μm (zoom). B. CpFBA in the CpESPs was detected using anti-CpFBA serum by Western blot. Lane M: molecular weight markers, lane 1: ESPs of C. parvum sporozoites. C. The mRNA levels of CpFBA at various developmental stages of C. parvum were detected by qPCR, data are expressed as mean ± SD from three independent experiments (n = 3). Statistical significance was evaluated using one-way ANOVA. Anti-CpFBA serum impairs parasite glycolysis and attenuates C. parvum infection in vitro To determine the roles of CpFBA on C. parvum proliferation and energy metabolism, antibody-mediated inhibition was used. Sporozoites were pre-treated with anti-CpFBA serum or pre-immune serum and then infected HCT-8 cells. Compared to pre-immune serum-treated sporozoites, sporozoites were incubated with anti-CpFBA serum showed reduced glucose uptake (Fig. 4A) and lower ATP levels (Fig. 4B). And compared to the pre-immune serum-treated C. parvum group, the number of C. parvum at 3 h post-infection in the 1:50, 1:100, and 1:200 anti-CpFBA serum treatment groups was reduced by approximately 42%, 21% and 10% respectively (Fig. 4C), and at 44 h post-infection, parasite numbers were further reduced by approximately 52%, 29% and 17% respectively (Fig. 4D). Western blot analysis showed that pre-immune serum-treated C. parvum infection significantly downregulated the tight junction proteins ZO-1 and occludin in HCT-8 cells, while the expression of these two proteins was partially restored by pre-treatment with anti-CpFBA serum at 1:50 and 1:100 (Fig. 4E). These data suggest that inhibiting CpFBA impairs parasite glycolysis, limits parasite invasion and proliferation, and mitigates infection-induced epithelial damage. Anti-CpFBA serum treament inhibits sporozoite energy metabolism and infection in HCT-8 cells. C. parvum sporozoites were incubated with anti-CpFBA serum at dilution ratios of 1:50, 1:100, and 1:200 or pre-immune serum at a dilution ratio of 1:50 (C.p) for 1 h, respectively. A. Glucose uptake by sporozoites. B. ATP levels in sporozoites. C. After pre-incubation, HCT-8 cells were infected with sporozoites for 3 h, and parasite load was detected by qPCR. D. After pre-incubation, HCT-8 cells were infected with sporozoites for 44 h, and parasite load was detected by qPCR. E. The expression levels of ZO-1 and occludin proteins were analyzed by Western blot and densitometric quantification. Data were presented as the mean ± SD from three independent experiments (n = 3), statistical significance was evaluated using one-way ANOVA (A-E) and unpaired Student's t-test (E). Morin inhibits parasite glycolysis and suppresses C. parvum infection in vitro Given the significance of the aforementioned findings regarding CpFBA in C. parvum, and considering the research reported that morin inhibited Eimeria tenella FBA activity and had an inhibitory effect on the development of E. tenella (Hu et al., 2022). We next investigated whether morin could suppress C. parvum infection. Molecular docking suggested that morin might bind to CpFBA, with a predicted binding energy of −8.4 kcal/mol, and formed a stable interaction with CpFBA (Fig. 5A). Enzyme kinetics confirmed that morin inhibited rCpFBA activity in a dose-dependent manner, with a half-maximal inhibitory concentration (IC50) of 20.12 μM (Fig. 5B). Compared to DMSO-treated sporozoites, treatment with 12.5, 25 or 50 μM morin significantly inhibited glucose uptake (Fig. 5C) and ATP production (Fig. 5D) in a concentration-dependent manner. SEM observation revealed that morin treatment induced marked morphological alterations in sporozoites, including surface wrinkling, invaginations, protrusions, and swelling, whereas DMSO-treated sporozoites retained smooth, fusiform contours (Fig. 5E). Morin resists sporozoites energy metabolism and infection in HCT-8 cells. A. The predicted binding conformation of morin with CpFBA plotted with Pymol. B. Analysis of the inhibitory effect of morin on rCpFBA activity. GraphPad Prism 9.5 was used to fit nonlinear regression curves and calculate IC50 values. C. Sporozoites were incubated with DMSO (C.p), 12.5, 25, and 50 μM morin (M + C.p) for 1 h respectively. Glucose intake and D. ATP levels in sporozoites. E. Sporozoites were incubated with DMSO (Control) or 50 μM morin, and the morphology of sporozoites was observed by SEM. The white arrows indicate invagination, the orange arrows indicate protrusion, and the red arrows indicate swelling. HCT-8 cells were infected with the C. parvum sporozoites that were incubated with DMSO (C.p), 12.5, 25, and 50 μM morin for 1 h. F. HCT-8 cells were infected with sporozoites for 3 h, the number of sporozoites in HCT-8 cells was quantified by qPCR. G. HCT-8 cells were infected with sporozoites for 44 h, the number of sporozoites in HCT-8 cells was quantified by qPCR. H. The expression levels of ZO-1 and Occludin proteins were analyzed by Western blot and densitometric quantification. Data were presented as the mean ± SD from three replicate assays (n = 3), statistical significance was evaluated using one-way ANOVA (C, D, F-H) and unpaired Student's t-test (H). Subsequently, to further evaluate the role of morin in C. parvum infection, sporozoites were pre-incubated with morin before infecting HCT-8 cells. Pre-incubation with morin at 12.5 μM, 25 μM and 50 μM significantly reduced parasite invasion (at 3 h) by approximately 11%, 24% and 51%, respectively (Fig. 5F), and suppressed proliferation (at 44 h) by approximately 13%, 31% and 56% compared to the DMSO-treated C. parvum group (Fig. 5G). Moreover, morin treatment reversed the downregulation of ZO-1 and occludin proteins induced by C. parvum infection (Fig. 5H). Collectively, these results indicate that morin inhibits CpFBA enzymatic activity and parasite glycolysis, causes structural damage in the parasite, impairs invasion and proliferation and attenuation of intestinal barrier disruption. Morin alleviates C. parvum infection and intestinal pathology in suckling mice To investigate the efficacy of morin against C. parvum infection in vivo, suckling mice were infected with oocysts and then treated with morin via oral gavage for 5 days (Fig. 6A). Compared to the C. parvum group, morin significantly reduced fecal oocyst shedding by 20.3%, 52.8%, and 61.8% in the 20, 40, and 60 mg/kg/day treatment groups, respectively (Fig. 6B), and suppressed C. parvum infection-induced upregulation of IL-6, IL-12, and TNF-α mRNA levels in the ileum (Fig. 6C–E). Furthermore, H&E staining revealed that C. parvum infection caused severe villous atrophy, epithelial erosion, and crypt hyperplasia, which were markedly attenuated by morin treatment at 40 and 60 mg/kg/day (Fig. 6F–H). AB-PAS staining further showed that C. parvum infection significantly reduced goblet cell numbers, which were effectively restored by morin in a dose-dependent manner (Fig. 6I and J). Consistent with these protective effects, morin treatment dose-dependently attenuated C. parvum-induced the reduction of ZO-1 and Occludin (Fig. 7). Collectively, these results demonstrate that morin exerts potent anti-cryptosporidial effects by reducing parasite burden, mitigating infection-associated inflammation, and preserving intestinal barrier integrity. Morin treatment inhibits the proliferation of parasites, alleviates inflammatory responses and intestinal damage in suckling mice. A. The suckling mice (n = 5 per group) were infected with C. parvum via intragastric gavage on day 1, and subsequently administered 50 μL PBS, morin (20, 40, or 60 mg/kg/day) or solvent (2% DMSO + 10% PEG 400 + 88% saline) via intragastric gavage for 5 days, then the suckling mice were euthanized and their ileum tissues and feces were collected. B. The number of oocysts in the feces of suckling mice was detected by qPCR. C-E. The mRNA levels of IL-6, IL-12, and TNF-α in the ileum tissues of suckling mice were detected by qPCR. F. Images of H&E staining of mouse ileum, scale bar = 50 μm. G. The villus length and crypt depth. H. Histopathological score of ileum. I. AB-PAS staining of ileum of suckling mice, scale bar = 50 μm. J. The number of goblet cells in per villus was quantified using ImageJ. All data were presented as the mean ± SD from three replicate assays, statistical significance was evaluated using one-way ANOVA. Morin alleviates intestinal barrier injury caused by C. parvum in suckling mice. A, B. The expression levels of ZO-1 and occludin in ileum were detected by IFA (n = 5), scale bar = 50 μm. Green represents ZO-1 and occludin, red represents C. parvum. C. The expression levels of ZO-1 and occludin proteins in suckling mice ileum were detected by Western blot, and densitometric quantification. All data were presented as the mean ± SD from three replicate assays, statistical significance was evaluated using one-way ANOVA. Discussion FBA is a core glycolytic enzyme present in various pathogens. In this study, we identified a single FBA homolog in C. parvum. CpFBA clusters closely with aldolases from T. gondii, Plasmodium spp., and Eimeria spp., underscoring a deep evolutionary conservation of this enzyme within the phylum. In T. gondii and Eimeria tenella, aldolase serves as a critical bridge linking surface adhesins to the parasite's actin cytoskeleton, which is essential for host cell invasion and gliding motility. This dual role, combining metabolic and structural functions, positions FBA as an attractive and potentially vulnerable target for antiparasitic intervention (Hu et al., 2022; Tonkin et al., 2015). Our findings confirm that CpFBA is indispensable for glycolysis, invasion, and proliferation of C. parvum, suggesting it is a vulnerable antiparasitic target. The transcriptional levels and subcellular localization of parasite molecules at different developmental stages are related to the molecule functions in parasite development. Our study revealed that CpFBA transcript levels peaked in the early stages of C. parvum infection, coinciding with the energy-demanding processes of the parasite invasion and initial intracellular establishment. The parasite cytoplasm serves as the site where canonical glycolytic enzymes exert their activity (He et al., 2021). We found that CpFBA was localized in the cytoplasm of C. parvum sporozoites. Notably, CpFBA was detected on the sporozoite membrane and in ESPs. This extracellular and membrane-associated presence aligns with reports of aldolase acting as a surface adhesin in other pathogens, including M. bovis and Mycoplasma hyopneumoniae, and this feature is associated with adhesion to host cells and invasion process (Gao et al., 2018; Yu et al., 2018). Given that C. parvum relies almost exclusively on glycolysis for ATP production due to its lack of a functional tricarboxylic acid cycle and oxidative phosphorylation (Xu et al., 2024), interference with key glycolytic enzymes is anticipated to compromise these critical steps. In this study, blocking CpFBA significantly impaired glucose uptake and depleted intracellular ATP, consistent with a sugar metabolic defect. Simultaneously, blocking CpFBA reduced parasite invasion and proliferation in vitro and attenuated infection-induced damage to host epithelial tight junctions (ZO-1, occludin). These observations are similar to previous reports showing that anti-FBA antibodies inhibit Mycoplasma spp. adhesion and invasion (Yu et al., 2018; Huang et al., 2019b). Therefore, CpFBA likely participates in parasite adhesion while also providing energy for C. parvum, and the anti-parasitic effect of anti-CpFBA serum likely involves a combination of both mechanisms. Our findings suggest that CpFBA may be a virulence factor of C. parvum and highlight its potential as a therapeutic target. Future studies using gene knockout or specific inhibitors that dissociate the catalytic and adhesive functions are needed to resolve the precise mechanism. Morin, a flavonoid derived from traditional Chinese herbs, is known for its anti-inflammatory, antioxidant, and antimicrobial properties (Qiu et al., 2024; Li et al., 2017, 2020). Recent studies have shown that morin can inhibit S. aureus, Vibrio cholerae, and coronavirus (Gupta et al., 2022; Nag et al., 2021; Chemmugil et al., 2019). Notably, morin also inhibits E. tenella FBA activity and protects against E. tenella infection (Hu et al., 2022). Based on these findings, we further investigated whether morin exerts a similar inhibitory effect on CpFBA enzymatic activity. Here, we first performed molecular docking between CpFBA and morin. Interestingly, morin was predicted to bind to CpFBA, with a predicted binding energy of −8.4 kcal/mol. Subsequent experiments showed that morin inhibited CpFBA enzymatic activity and reduced parasite glucose uptake and ATP levels, indicating that morin may suppress the glycolytic process of C. parvum. Given that C. parvum relies primarily on glycolysis for energy production (Xu et al., 2024), these results suggest that morin may possess anti-C. parvum efficacy. Subsequently, we further demonstrated that morin treatment disrupted parasite morphology, and inhibited C. parvum infection in vitro. In a suckling mouse model, morin treatment (60 mg/kg/day) significantly reduced oocyst shedding (by up to 61.8%), alleviated intestinal damage, and suppressed the infection-driven pro-inflammatory cytokine response. For comparison, nitazoxanide has been reported to reduce C. parvum oocyst shedding to approximately 42% in a similar neonatal mouse model (Blagburn et al., 1998). Importantly, histopathological examination and assessment of intestinal barrier integrity revealed that morin treatment (60 mg/kg/day) did not cause detectable damage to intestinal tissue, suggesting that morin is a potentially safe and effective anti-C. parvum candidate. Unfortunately, the oral bioavailability of flavonoids is generally low (Naeem et al., 2022). One study reported that the oral bioavailability of morin in rats is only 0.45% (Li et al., 2019b). To address this limitation, researchers have encapsulated morin in lipid core/PLGA shell nanoparticles, achieving a 5.6-fold increase in oral bioavailability and a significantly prolonged half-life in mice (Sunoqrot et al., 2023). These findings indicate that the bioavailability of morin can be improved through formulation optimization, and future studies using nanocarrier-based delivery systems may further enhance its anti-C. parvum efficacy. Nevertheless, we are currently unable to determine the exact mechanism of morin's anti-C. parvum effect, as our research revealed that the IC50 of morin against rCpFBA (∼20 μM) is modest, it raises the possibility that morin may act through promiscuous or non-specific interactions. Morin is known to target multiple enzymes, including host ACE2, IMP-α, and PARP-1; the spike glycoprotein, main protease 3CLPro and papain-like protease PLPro of SARS-CoV-2, SARS-CoV and MERS-CoV; and the global regulator SarA of S. aureus (Gupta et al., 2022; Nag et al., 2021; Chemmugil et al., 2019). Therefore, it is plausible that its anti-C. parvum effects involve additional parasite or host targets. Moreover, morin has well-documented anti-inflammatory properties. For instance, morin alleviates histopathological damage in mammary tissue and reduces the production of TNF-α, IL-1β, and IL-6 in mastitis (Yu et al., 2020). Furthermore, in a mouse model of DSS-induced colitis, morin treatment reduces the mRNA levels of IL-6, IL-12, and TNF-α in the ileum, accompanied by restoration of ZO-1 and occludin and attenuation of histological damage (Qiu et al., 2024). Thus, the observed reductions in cytokine expression (IL-6, IL-12, TNF-α) and intestinal damage in morin-treated mice could be partially driven by host modulation. Consequently, the anti-C. parvum effect of morin likely stems from a dual mechanism, it may act on the parasite, which inhibits parasite glycolysis and invasion, and coupled with its well-documented anti-inflammatory and antioxidant properties to mitigate host tissue damage. Conclusion This study establishes that CpFBA is a conserved, multifunctional enzyme essential for energy metabolism, invasion, and proliferation of C. parvum. Furthermore, morin not only inhibits CpFBA enzymatic activity, parasite glycolysis and disrupts parasite morphology, but also suppresses C. parvum infection and alleviates intestinal inflammation and tissue damage. These findings validate CpFBA as a novel druggable target and identify morin as a promising candidate for anti-cryptosporidial therapy. Collectively, this work provides a foundation for targeting glycolytic enzymes in C. parvum and highlights the potential of natural flavonoids as lead compounds for future drug development. Ethical approval All animal procedures were approved by the Animal Welfare and Research Ethics Committee of Jilin University (Approval No. 202407009). Funding This work was supported by the National Key Research and Development Program of China (2023YFD1801003), the National Natural Science Foundation of China (32373034), and the Jilin Provincial Scientific and Technological Development Program (20240303078NC). CRediT authorship contribution statement Mengge Chen: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Writing – original draft. Hongyan Kang: Data curation, Investigation, Methodology, Software. Yanhui Yu: Methodology, Validation. Xuancheng Zhang: Data curation, Methodology, Supervision. Xu Zhang: Conceptualization, Methodology, Writing – review & editing. Xiaocen Wang: Conceptualization, Methodology, Validation. Zhenzhen Liu: Methodology. Yuan Zheng: Validation. Pengtao Gong: Supervision. Nan Zhang: Supervision. Xin Li: Conceptualization, Funding acquisition, Methodology, Writing – review & editing. Jianhua Li: Conceptualization, Funding acquisition, Methodology, Supervision, Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgments We appreciate Professor Zhu Guan from Jilin University for providing the parasite that has been labeled with a pan-Cryptosporidium (Pan-Crypto) antibody, and Wuhan Servicebio Technology Co., Ltd. for the paraffin sections. Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.ijpddr.2026.100653. Contributor Information Xin Li, Email: lixin2018@jlu.edu.cn. Jianhua Li, Email: jianhuali7207@163.com. Supplementary data The following are the Supplementary data to this article: Multimedia component 1 CpFBA gene amplification and vector construction. A. Amplification of CpFBA gene by PCR. Lane M: molecular weight markers, lane 1: The PCR amplification of CpFBA gene. B. Identification of recombinant plasmid pGEX-4T-1-CpFBA by restriction enzyme digestion. Lane M: molecular weight markers, lane 1: the recombinant plasmid pGEX-4T-1-CpFBA, lane 2: the recombinant plasmid pGEX-4T-1-CpFBA after treatment with restriction endonuclease. Recombinant expression and identification of CpFBA. A. Expression of rCpFBA was analyzed by SDS-PAGE. Lane M: molecular weight markers, lane 1: lysate from bacteria with pGEX-4T-1 empty vector, lane 2: lysate from recombinant bacteria without IPTG induction, lane 3: lysate from IPTG-induced recombinant bacteria, lane 4: supernatant of IPTG-induced recombinant bacterial culture, lane 5: pellet of lysate from IPTG-induced recombinant bacteria. B. Purification of rCpFBA was analyzed by SDS-PAGE. Lane M: molecular weight markers, lane 1: bacteria fragmentation supernatant, lane 2: flow-through solution, lane 3: wash solution, lane 4: elution I, lane 5: elution II. C. rCpFBA protein was analyzed by western blot. Lane M: molecular weight markers, lane 1: purified rCpFBA. D. Detection of native CpFBA protein in C. parvum sporozoites by western blot using anti-CpFBA serum. Lane M: molecular weight markers, lane 1: C. parvum sporozoites lysate supernatant. E. The rCpFBA was analyzed using anti-CpFBA serum by western blot. Lane M: molecular weight markers, lane 1: purified rCpFBA. Data availability Raw data supporting the findings of this study were deposited on Figshare at https://doi.org/10.6084/m9.figshare.31851958. References Associated Data Supplementary Materials Multimedia component 1 Data Availability Statement Raw data supporting the findings of this study were deposited on Figshare at https://doi.org/10.6084/m9.figshare.31851958.